Senior Accountant

Are you ready to join a team committed to making a meaningful impact on cancer treatment through the discovery and development of precision medicines? At Kura Oncology, you have an opportunity to be a part of something bigger, with a lasting impact that you can be proud of.

At Kura Oncology, we are working to change the paradigm and improve the science of cancer treatment. As an organization, we strive to cultivate a diverse and talented professional culture driven to develop precision medicine therapeutics.

As we continue to build a leading biotech organization with a strong culture, a patient-focused mindset and a team focused on relentless execution, we are looking for innovative, passionate professionals to join us and make our vision a reality.

To succeed at Kura, you will need to have a demonstrated ability for excellence in drug discovery and development and a roll-up your sleeves attitude. The ideal candidate will possess a values-driven work style where integrity and grit drive all behaviors, decisions, and actions.

ESSENTIAL JOB FUNCTIONS:

• Prepare monthly/quarterly journal entries for prepaids, depreciation of fixed assets, capitalized software, and commercial and G&A accruals.
• Prepare monthly reconciliations for various accounts, including but not limited to bank reconciliations, prepaids, fixed assets, long-term assets, G&A and commercial accrued contracts, software capitalization, etc.
• Collaborate with business owners and functional leaders to obtain contracts and project progress and information to ensure timely and accurate accruals.
• Analyze contracts and collaborate with functional owners to appropriately capture capitalized software and fixed assets.
• Prepare monthly and quarterly variance analyses for various accounts and projects.
• Perform monthly close activities such as preparing monthly trial balance and reporting.
• Review invoice and purchase order coding for assigned departments.
• Prepare and submit property tax filing for various locations and ad hoc reporting.
• Ensure accuracy and compliance with GAAP and Sarbanes Oxley policy and procedures.
• Support financial and SOX reviews and audits - gather information, prepare schedules as needed.
• Responsible for quarterly related party updates and support, including related party inquiries, related party memo update, and transactional JE’s and analysis.
• Responsible for overseeing and reviewing the R&D by location reporting for taxes and census reporting.
• Perform other duties and ad hoc projects, as assigned, to support the Finance department.

JOB SPECIFICATIONS:

• Bachelor’s degree in accounting, or other related discipline, or the equivalent knowledge and experience required.
• A minimum of 5 years’ relevant accounting experience, preferably in a combination of the following monthly close process, bank reconciliations, balance sheet reconciliations, contract accruals
• Excellent communication and people skills and the ability to interface with various levels of co-workers, upper management, and external customers while maintaining a high degree of confidentiality.
• Experience working in publicly traded company and life science industry preferred.
• Knowledge of US GAAP and internal control principles for a public corporation.
• ERP experience required; experience with NetSuite, Blackline, Coupa and Concur preferred.
• Skilled in the use of Microsoft Office Suite with intermediate to advanced Excel skills.
• Detail oriented with good analytical skills.
• Strong time management skills and ability to independently organize multiple tasks of varying priorities and meet critical deadlines in a fast-paced environment.
• Ability to work in team environment and willing to assist other team members to achieve team goals and objectives.

The base range for this role is $95,264 - $117,022. Individual pay may vary based on additional factors, including, and without limitation, job-related skills, experience, work location, and relevant education or training. Kura's compensation package also includes generous benefits, equity, and participation in an annual target bonus.

#LI-RM1

Kura’s Values that are used for candidate selection and performance assessments:

• We work as one for patients
• We are goal-focused and deliver with excellence
• We are science-driven courageous innovators
• We strive to bring out the best in each other and ourselves

The Kura Package

• Career advancement/ development opportunities
• Competitive comp package
• Bonus
• 401K + Employer contributions
• Generous stock options
• ESPP Plan
• 20 days of PTO to start
• 18 Holidays  (Including Summer & Winter Break)
• Generous Benefits Package with a variety of plans available with a substantial employer match
• Paid Paternity/Maternity Leave
• In-Office Catered lunches
• Home Office Setup
• Lifestyle Spending Stipend
• Commuter Stipend (Boston Office)
• Regular employee social activities, including happy hours, monthly birthday celebrations, Kura Koffee Talks, and much more!

Kura Oncology is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. The Company’s pipeline consists of small molecule drug candidates designed to target cancer signaling pathways. Ziftomenib, a once-daily, oral menin inhibitor, is the first and only investigational therapy to receive Breakthrough Therapy Designation from the U.S. Food and Drug Administration (“FDA”) for the treatment of relapsed/refractory (“R/R”) NPM1-mutant acute myeloid leukemia (“AML”). In November 2024, Kura Oncology entered into a global strategic collaboration agreement with Kyowa Kirin Co., Ltd. to develop and commercialize ziftomenib for AML and other hematologic malignancies. Enrollment in a Phase 2 registration-directed trial of ziftomenib in R/R NPM1-mutant AML has been completed, and in the second quarter of 2025, the companies announced the FDA’s acceptance of a New Drug Application for ziftomenib for the treatment of adult patients with R/R NPM1-mutant AML and assignment of a Prescription Drug User Fee Act target action date of November 30, 2025. Kura Oncology and Kyowa Kirin are also conducting a series of clinical trials to evaluate ziftomenib in combination with current standards of care in newly diagnosed and R/R NPM1-mutant and KMT2A-rearranged AML. KO-2806, a next-generation farnesyl transferase inhibitor, is being evaluated in a Phase 1 dose-escalation trial as a monotherapy and in combination with targeted therapies for patients with various solid tumors. Tipifarnib, a potent and selective farnesyl transferase inhibitor, is currently in a Phase 1/2 trial in combination with alpelisib for patients with PIK3CA-dependent head and neck squamous cell carcinoma. For additional information, please visit Kura’s website at www.kuraoncology.com and follow us on X and LinkedIn.

Kura Oncology is committed to creating a diverse environment and is proud to be an equal opportunity employer. All qualified applicants will receive consideration for employment without regard to race, color, religion, gender, gender identity or expression, sexual orientation, national origin, genetics, disability, age, or veteran status. 

If you are a California resident, please see the attached Privacy Notice CA Privacy Notice